Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Income from Continuing Operations (2017 - 2025)

Cue Biopharma's Income from Continuing Operations history spans 9 years, with the latest figure at 7314000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 13.68% year-over-year to 7314000.0; the TTM value through Sep 2025 reached 37224000.0, up 14.35%, while the annual FY2024 figure was 39878000.0, 19.42% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 7314000.0 at Cue Biopharma, up from 8438000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 7314000.0 in Q3 2025 and bottomed at 14255000.0 in Q1 2022.
  • The 5-year median for Income from Continuing Operations is 12106000.0 (2024), against an average of 11232377.63.
  • The largest annual shift saw Income from Continuing Operations plummeted 80.42% in 2022 before it rose 27.72% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 7889175.0 in 2021, then tumbled by 80.42% to 14234000.0 in 2022, then increased by 9.18% to 12927000.0 in 2023, then grew by 27.72% to 9343000.0 in 2024, then rose by 21.72% to 7314000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Income from Continuing Operations are 7314000.0 (Q3 2025), 8438000.0 (Q2 2025), and 12129000.0 (Q1 2025).